Influence of-141C Ins/Del polymorphism in DRD2 gene on clinical symptoms and plasma homovanillic acid levels in the treatment of schizophrenia with aripiprazole

Journal of Clinical Psychopharmacology

Volumn 35, Issue 3, 2015, Pages 333-334

  Miura, Itaru ^a   Kanno Nozaki, Keiko ^a   Hino, Mizuki ^a   Horikoshi, Sho ^a   Ota, Takafumi ^a   Mashiko, Hirobumi ^a   Niwa, Shin Ichi ^a   Yabe, Hirooki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ARIPIPRAZOLE; CERIUM 141; DOPAMINE 2 RECEPTOR; HOMOVANILLIC ACID; MONOAMINE; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ALLELE; DNA POLYMORPHISM; GENOTYPE; HUMAN; INDEL MUTATION; JAPANESE (PEOPLE); LETTER; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STUDY DESIGN; ADULT; BLOOD; FEMALE; GENETICS; MALE; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; FEMALE; HOMOVANILLIC ACID; HUMANS; INDEL MUTATION; MALE; METHOXYHYDROXYPHENYLGLYCOL; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84929161873     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000330     Document Type: Letter

References (10)

1. Himei A, Koh J, Sakai J, et al. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and-141C Ins/Del polymorphisms. Psychiatry Clin Neurosci. 2002; 56 (1): 97-102.
2. Dolzan V, Plesnicar BK, Serretti A, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B (6): 809-815.
3. Shen YC, Chen SF, Chen CH, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res. 2009; 43 (6): 600-606.
4. Zhang JP, Lencz T, Malhotra AK,. et al. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010; 167 (7): 763-772.
5. Zahari Z, Teh LK, Ismail R, Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatr Genet. 2011; 21 (4): 183-189.
6. Miura I, Takeuchi S, Katsumi A, Effects of aripiprazole and the Taq 1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. J Clin Psychopharmacol. 2012; 32 (1): 106-109.
7. Jönsson EG, Nöthen MM, Grünhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999; 4 (3): 290-296.
8. Arinami T, Gao M, Hamaguchi H, et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997; 6 (4): 577-582.
9. Ujike H, Katsu T, Okahisa Y, et al. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33 (4): 625-629.
10. Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012; 66 (6): 518-524.